Safety and efficacy of candesartan versus valsartan combined with amlodipine on peripheral and central blood pressure.

Autor: Hanna SM; Clinical Pharmacist, Cardiovascular Department, Beni-Suef University Hospital, Egypt. Electronic address: selviahanna@yahoo.com., Rabea HM; Clinical Pharmacy Department, Faculty of Pharmacy, Beni-Suef University, Beni-Suef, Egypt., Abdelrahim MEA; Clinical Pharmacy Department, Faculty of Pharmacy, Beni-Suef University, Beni-Suef, Egypt., Mahmoud HB; Prof. of Cardiology, Beni-Suef University Hospital, Beni-Suef, Egypt.
Jazyk: angličtina
Zdroj: Hipertension y riesgo vascular [Hipertens Riesgo Vasc] 2024 Jan-Mar; Vol. 41 (1), pp. 17-25. Date of Electronic Publication: 2024 Feb 28.
DOI: 10.1016/j.hipert.2023.11.004
Abstrakt: Introduction: "Amlodipine/valsartan" or "amlodipine/candesartan" combinations represent two effective antihypertensive agents with complementary mechanisms of action. Nevertheless, a study has yet to be done to evaluate the effect of amlodipine/candesartan on central blood pressure and compare it with amlodipine/valsartan combination. To see how "amlodipine plus candesartan combination" reduces peripheral and central blood pressure compared to the most studied combination, "amlodipine plus valsartan".
Material and Methods: Eighty-six patients were randomized in an open-label, prospective study by 1:1 ratio to two groups. Group I (n=42) received the amlodipine and valsartan combination, and group II (n=44) received the amlodipine and candesartan combination. Peripheral and central blood pressure (CBP) was measured at baseline, at 6 and 12 weeks of follow-up.
Discussion: Both treatment groups reduced peripheral systolic, diastolic, and mean blood pressure. There was no significant difference between and within both groups. The amlodipine/candesartan combination showed more reduction in peripheral systolic blood pressure (PSBP) after 12 weeks of treatment (p=<0.001). Both groups decreased CBP without significant differences between groups. The amlodipine/candesartan combination showed additional efficacy in decreasing CSBP after 12 weeks (p=<0.001). The two treatment groups did not exert significant efficacy in lowering heart rate (HR) and augmentation index% (AIx%).
Conclusion: To conclude, the amlodipine 10mg/candesartan 16mg combination was non-inferior to the amlodipine 10mg/valsartan 160mg combination in terms of reducing peripheral and CBP over time.
(Copyright © 2024 SEH-LELHA. Publicado por Elsevier España, S.L.U. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: